Issues
Cancer Research
Table of Contents
Advances in Brief
A Superagonist Variant of Peptide MART1/Melan A27–35 Elicits Anti-Melanoma CD8+ T Cells with Enhanced Functional Characteristics: Implication for More Effective Immunotherapy1
Somatic Mutations in the Kinase Domain of the Met/Hepatocyte Growth Factor Receptor Gene in Childhood Hepatocellular Carcinomas1
Mutational Inactivation of Transforming Growth Factor β Receptor Type II in Microsatellite Stable Colon Cancers1
A Novel Synthetic Oleanane Triterpenoid, 2-Cyano-3,12-dioxoolean-1,9-dien-28-oic Acid, with Potent Differentiating, Antiproliferative, and Anti-Inflammatory Activity1
Transcription Factor Y-Box Binding Protein 1 Binds Preferentially to Cisplatin-modified DNA and Interacts with Proliferating Cell Nuclear Antigen1
Biochemistry
Carcinogenesis
Endocrinology
Experimental Therapeutics
Signaling Pathway Activated during Apoptosis of the Prostate Cancer Cell Line LNCaP: Overexpression of Caspase-7 as a New Gene Therapy Strategy for Prostate Cancer1
Immunology
Molecular Biology and Genetics
Tumor Biology
Enhanced Production and Activation of Progelatinase A Mediated by Membrane-Type 1 Matrix Metalloproteinase in Human Papillary Thyroid Carcinomas1
Meeting Report
Journal Archive
Cancer Research
(1941-Present; volumes 1-current)Published twice monthly since 1987. From 1941-1986, published monthly.
(ISSN 0008-5472)
The American Journal of Cancer
(1931-1940; volumes 15-40)Published quarterly in 1931, bimonthly in 1932, and monthly from 1933 to 1940. The journal changed title to Cancer Research in 1941.
(ISSN 0099-7374)
The Journal of Cancer Research
(1916-1930); volumes 1-14)Published quarterly from 1916 through 1930 (publication was suspended from November 1922 to March 1924). The journal changed title to The American Journal of Cancer in 1931.
(ISSN 0099-7013)
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale—within the United States—of Bavencio® (avelumab), a pharmaceutical owned by Merck. None of these funds are being, or will be, used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.